Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Inclusion criteria

• patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III;
• estimated survival \> 3 months;
• presence of clinically measurable lesions;
• Karnofsky functional status score ≥ 70;
• normal routine blood test results, normal liver and kidney function, and near normal electrocardiographic manifestations;
• age at 18-70 years.

Exclusion criteria

• stage IV breast cancer patients with bone metastasis or other distant metastasis;
• severe renal insufficiency;
• older adult patients with severe organic diseases such as heart and lung diseases, who are not estimated to be able to tolerate chemotherapy;
• those who have received antineoplastic therapy;
• those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy;
• those with history of other malignant tumors;
• those with severe heart, liver, and kidney organ dysfunction or poor health who cannot tolerate chemotherapy, or those who cannot tolerate chemotherapy and switch to other therapeutic regimens;
• those with mental and nervous system diseases who cannot comply with treatment;
• those with dexamethasone intolerance or those who are highly allergic to any drug in neoadjuvant chemotherapy;
• pregnant or lactating women;
• those who are participating in other trials.